NCT06213233招募中2 期
Pragmatic Trial of Cannabidiol to Improve Chronic Pain Symptoms Among Veterans
Kevin Boehnke2 个研究点 分布在 1 个国家目标入组 468 人开始时间: 2024年2月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 468
- 试验地点
- 2
- 主要终点
- Global impression of change (PGIC) between groups at end of treatment (Day 28)
研究概览
简要总结
This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain.
Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period.
The study hypotheses:
- CBD would improve overall pain symptoms compared to placebo
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures
- •Armed Services Veteran
- •All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study.
- •Reports moderate to severe chronic pain defined by protocol
- •Currently using or interested in using cannabis for pain management
- •Self-reported willingness to refrain from or not increase current Tetrahydrocannabinol (THC) or other cannabis product use (including CBD) during the study intervention or other cannabinoid use during the study intervention
- •Individuals of reproductive potential must agree to use acceptable birth control per protocol
- •Participants must also agree not to donate sperm or eggs during study drug administration
- •Willingness to attend all study visits (may be done virtually)
- •Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen
- •Willingness to wear Fitbit or other similar sensor for passive-data collection
- •Willingness to fill out daily diary via smartphone to assess symptom status, study drug use, and other cannabis use
排除标准
- •Not an Armed Services Veteran
- •Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)
- •Participant reports pregnancy or are nursing
- •Planning to move out of a state with legal recreational marijuana use during course of study
- •Risk for imminent harm - Suicidal ideation or wish to die as assessed per protocol
- •Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
- •Participation in any other clinical trials over the course of this study
- •Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)
- •Having a serious or unstable hepatic disease (e.g., non-alcoholic fatty liver disease or liver cirrhosis)
- •Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, and seizures
- •Recent/new diagnosis of cancer within the past 3 years (other than localized melanoma, localized basal cell carcinoma, localized squamous cell carcinoma treated or untreated)
- •Current valproate and clobazam use per self-report or medical records
- •Self-reported allergies to sesame oil or cannabis/cannabinoids
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Cannabidiol
Experimental
干预措施: Cannabidiol (Drug)
结局指标
主要结局
Global impression of change (PGIC) between groups at end of treatment (Day 28)
时间窗: Day 28
This is a 1-item survey that measures patient perceptions of intervention success. This survey is scored from 1 to 7, where lower scores indicate a better outcome.
次要结局
- Anxiety based on the Patient Reported Outcomes Measurement Information System (PROMIS)-29+2 Profile v2.1(Days 1-28)
- Sleep disturbance based on the Patient Reported Outcomes Measurement Information System (PROMIS)-29+2 Profile v2.1(Days 1-28)
- Chronic pain severity between groups in the study period (Days 1 - 28)(Days 1-28)
- Change in suicidal ideation based on the Negative Suicide Ideation questionnaire (PANSI)(Baseline (day 1), 28)
- Change in pain interference based on the pain interference 4a short form items from the Patient Reported Outcomes Measurement Information System (PROMIS)-29+2 Profile v2.1(baseline (day 1), day 28)
- Change in suicidal ideation based on Positive and Negative Suicide Ideation (PANSI) Inventory(Baseline (day 1), 28)
- Safety assessed by the number of adverse events that are possibly, probably, or definitely related to the study drug between groups(Days 1-28)
研究者
Kevin Boehnke
Assistant Professor
University of Michigan
研究点 (2)
Loading locations...
相似试验
Unknown
早期 1 期
Cannabidiol (CBD) for the Treatment of Alcohol WithdrawalAlcohol WithdrawalAlcohol DependenceNCT04205682South West Sydney Local Health District52
终止
3 期
Cannabidiol and Management of Endometriosis PainCBDPelvic PainEndometriosisNCT04527003Milton S. Hershey Medical Center12
Unknown
2 期
CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate SymptomsSARS-CoV2NCT04467918University of Sao Paulo100
已完成
2 期
A Clinical Trial on the Antipsychotic Properties of CannabidiolPsychotic DisordersSchizophreniaNCT00309413University of Cologne29
暂停
2 期
Use of CBD Oil in the Treatment of Posttraumatic Stress DisorderPost Traumatic Stress DisorderNCT04197102University of Texas at Austin150